Lexatumumab

DB06599InvestigationalProtein Based Therapies

Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

Mechanism: Lexatumumab agonizes the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), triggering the extrinsic apoptotic pathway.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Code names: ETR2-ST01 · HGS-1018 · HGS-ETR2 · TRAIL-R2

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lexatumumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.